Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Top Cited Papers
- 30 May 2017
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 18 (7), 904-916
- https://doi.org/10.1016/s1470-2045(17)30376-5
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trialThe Lancet Oncology, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO StudyJournal of Clinical Oncology, 2012
- Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral BloodClinical Cancer Research, 2012
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast CancerCancer Discovery, 2011
- Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric testsBiometrical Journal, 2011
- Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancerBreast Cancer Research, 2011
- Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast CancerJournal of Clinical Oncology, 2010
- Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancerJCI Insight, 2010